Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy, adjusts target to $40 (reverse stock split - 1:20).
Posted In: CDTX